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Abstract 
 
Infectious diseases such as HIV, tuberculosis and malaria are endemic in Africa and often require concomitant 
treatments that may result into subsequent drug–drug interactions. Inter-individual variability in the 
pharmacokinetics and pharmacodynamics of drugs used in infectious diseases, as a result of genetic 
polymorphism, has been reported. Pharmacogenetics of HIV, TB and malaria treatments is inadequately 
described in the African population. This thesis describes the pharmacogenetic aspects of HIV, TB and malaria 
treatment focusing on the Ugandan population. 
Studies were conducted among Ugandan adult health volunteers (n=161) and HIV patients (n = 263), some of 
whom were co-infected with TB. Health volunteers were examined for the effect of sex and different single 
nucleotide polymorphisms (SNPs) in ABCB1, CYP2B6 and CYP3A5 genes on single dose pharmacokinetics of 
efavirenz (n=30) and quinine (n=20). Patients were examined for effects of rifampicin and CYP2B6 (*6 &*11), 
CYP3A5 (*3,*5 & *7) and ABCB1 (c.3435C>T & c.4036A>G) on enzyme induction, efavirenz clearance and 
efavirenz related CNS toxicities.  
 
Apparent efavirenz oral clearance in subjects homozygous to CYP2B6*6 and *11 was 21 and 20% lower than 
extensive metabolizers respectively, while efavirenz relative bioavailability was 26% higher in subjects 
homozygous for MDR1 (rs3842). A two-fold increase in apparent peripheral volume of distribution was 
associated with female sex. Comparisons of efavirenz pharmacokinetics between HIV and healthy volunteers 
revealed 30% decrease in its bioavailability with HIV/AIDS disease.  Long term enzyme induction during 
efavirenz treatment was greater without rifampicin than during rifampicin co-treatment and it majorly driven by 
CYP2B6 polymorphism rather than rifampicin treatment. Rifampicin co-treatment influenced neither efavirenz 
plasma concentrations nor incidence of efavirenz CNS toxicities (p = 0.8).   Additionally, efavirenz plasma 
concentrations dependent CNS side effects are common in HIV/AIDs patients.  
Thirty and thirteen fold variations in plasma quinine concentrations and quinine-to-3-hydroxyquinine metabolic 
ratio respectively, were observed. Plasma quinine concentration was significantly influenced ABCB1 haplotype, 
CYP3A5 genotype / haplotype as well as sex.  
 
CYP2B6 is the major predictor of efavirenz pharmacokinetics and pharmacodynamics with or without 
rifampicin co-treatment. CYP3A5 influences quinine but not efavirenz disposition while ABCB1 plays a role in 
disposition of both drugs. Pharmacogenetics rather than rifampicin co-treatment may determine efavirenz 
treatment outcomes in TB co-infected HIV patients treated with efavirenz and rifampicin based regimens.  
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